PMID- 36246602
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221019
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 13
DP  - 2022
TI  - Clinical risk factors of carbohydrate antigen-125, cytokeratin fragment 19, and 
      neuron-specific enolase in liver metastases from elderly lung cancer patients.
PG  - 1013253
LID - 10.3389/fgene.2022.1013253 [doi]
LID - 1013253
AB  - Objective: Lung cancer is a common malignant tumor characterized by challenging 
      detection and lack of specificity in clinical manifestations. To investigate the 
      correlation of tumor markers in the serum with liver metastasis and prognosis of 
      lung cancer. Methods: A total of 3,046 elderly lung cancer patients were 
      retrospectively studied between September 1999 and July 2020. Divided into liver 
      metastasis group and non-liver metastasis group. We compared a series of serum 
      biomarkers between the two groups of elderly patients to predict the prognosis in 
      patients with lung cancer by fluorescence in situ hybridization (FISH), advanced 
      flow cytometry (FCM) and multi tumor marker protein chip, including tumor markers 
      in the serum included alkaline phosphatase (ALP), serum calcium, hemoglobin (HB), 
      alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), neuron-specific enolase 
      (NSE), cytokeratin fragment 19 (Cyfra21-1), carbohydrate antigen-125 (CA-125), 
      carbohydrate antigen-153 (CA-153), carbohydrate antigen-199 (CA-199), and free 
      prostate specific antigen (free PSA). We used binary logistic regression analysis 
      to determine risk factors, and used receiver operating curve (ROC) analysis to 
      evaluate the diagnostic value of liver metastases in elderly patients with lung 
      cancer. Results: The proportion of lung cancer in the liver metastasis group was 
      higher than that observed in the non-liver metastases group. The expression 
      levels of CA-125, Cyfra21-1, and NSE in the liver metastasis group of lung cancer 
      were significantly higher than those reported in the non-liver metastases group 
      (p < 0.05). ROC curve analysis shows that the area under the curve of CA-125, 
      Cyfra21-1, and NSE are 0.614, 0.616 and 0.608, respectively. The sensitivity and 
      specificity of CA-125 were 45.70% and 76.20%, the sensitivity and specificity of 
      Cyfra21-1 were 60.10% and 57.10%, and the sensitivity and specificity of NSE were 
      44.10% and 75.00%, respectively. Conclusion: High levels of CA-125, Cyfra21-1, 
      and NSE in the serum may be associated with liver metastasis in elderly patients 
      with lung cancer. CA-125 and NSE are factors influencing the prognosis of elderly 
      patients with liver metastasis of lung cancer.
CI  - Copyright (c) 2022 Cheng, Chen, Ying, Wei, Shu, Kang, Zou, Ling, Liao, Wang and 
      Shao.
FAU - Cheng, Tao
AU  - Cheng T
AD  - Department of Respiratory, Shangrao People's Hospital of Nanchang University, 
      Shangrao, Jiangxi, China.
FAU - Chen, Jun
AU  - Chen J
AD  - Department of Ophthalmology, Jiangxi Branch of National Clinical Research Center 
      for Ocular Disease, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, China.
FAU - Ying, Ping
AU  - Ying P
AD  - Department of Ophthalmology, Jiangxi Branch of National Clinical Research Center 
      for Ocular Disease, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, China.
FAU - Wei, Hong
AU  - Wei H
AD  - Department of Ophthalmology, Jiangxi Branch of National Clinical Research Center 
      for Ocular Disease, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, China.
FAU - Shu, Huiye
AU  - Shu H
AD  - Department of Ophthalmology, Jiangxi Branch of National Clinical Research Center 
      for Ocular Disease, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, China.
FAU - Kang, Min
AU  - Kang M
AD  - Department of Ophthalmology, Jiangxi Branch of National Clinical Research Center 
      for Ocular Disease, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, China.
FAU - Zou, Jie
AU  - Zou J
AD  - Department of Ophthalmology, Jiangxi Branch of National Clinical Research Center 
      for Ocular Disease, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, China.
FAU - Ling, Qian
AU  - Ling Q
AD  - Department of Ophthalmology, Jiangxi Branch of National Clinical Research Center 
      for Ocular Disease, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, China.
FAU - Liao, Xulin
AU  - Liao X
AD  - Department of Ophthalmology and Visual Sciences, The Chinese University of Hong 
      Kong, Hong Kong, Hong Kong SAR, China.
FAU - Wang, Yixin
AU  - Wang Y
AD  - School of Optometry and Vision Science, Cardiff University, Cardiff, United 
      Kingdom.
FAU - Shao, Yi
AU  - Shao Y
AD  - Department of Ophthalmology, Jiangxi Branch of National Clinical Research Center 
      for Ocular Disease, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, China.
LA  - eng
PT  - Journal Article
DEP - 20220929
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC9557119
OTO - NOTNLM
OT  - CA-125
OT  - CYFRA21-1
OT  - NSE
OT  - liver metastasis
OT  - lung cancer
OT  - potential indicators
OT  - risk factors
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/18 06:00
MHDA- 2022/10/18 06:01
PMCR- 2022/09/29
CRDT- 2022/10/17 04:35
PHST- 2022/08/06 00:00 [received]
PHST- 2022/09/12 00:00 [accepted]
PHST- 2022/10/17 04:35 [entrez]
PHST- 2022/10/18 06:00 [pubmed]
PHST- 2022/10/18 06:01 [medline]
PHST- 2022/09/29 00:00 [pmc-release]
AID - 1013253 [pii]
AID - 10.3389/fgene.2022.1013253 [doi]
PST - epublish
SO  - Front Genet. 2022 Sep 29;13:1013253. doi: 10.3389/fgene.2022.1013253. eCollection 
      2022.